The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Long-term post hoc analysis of MURANO Trial: host immune changes following VenR treatment in CLL
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, reports on a study that assessed the long-term, post-treatment immune changes observed in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that participated in the MURANO phase III trial (NCT02005471). This analysis revealed that patients that completed the fixed-duration course of treatment with venetoclax and rituximab (VenR) demonstrated immune recovery with respect to their immunoglobulins and T-cell compartments. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, Astra Zeneca, BMS, Janssen, Roche/Genentech: Research Funding; Janssen, LAVA: Patents & Royalties: Pending; Astra Zeneca, BMS, Roche/Gennetech, Janssen, Abbvie, LAVA: Membership on an entity’s Board of Directors or advisory committees; Abbvie, Astra Zeneca, Janssen: Other: Speakers fee; Amsterdam UMC, University of Amsterdam: Current Employment
